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Introduction
Photocaging[1] has played an instrumental role in the spatio-
temporal control of biological processes.[2] It is based on the
temporary inactivation of a biologically active molecule
through conjugation with a photocleavable protecting group
(photocage), which can be conditionally removed by light ex-
posure to reactivate the molecule (Scheme 1). The concept of
photocaging has been extensively demonstrated in the control
of cellular activities in vitro such as channel gating,[1] protein
activation,[3] and gene regulation[2, 4] as well as in the develop-
ment of optogenetic animal models in vivo.[4b, c]
Protecting groups for photocaging are primarily composed
of UV or visible light-responsive aromatic ring structures that
include ortho-nitrobenzene (ONB),[1] nitro-benzofuran,[5] 6-
bromo-7-hydroxycoumarin (BHC),[6] quinolone,[7] and cyanine.[8]
Recently, the use of these cage molecules has been expanded
to areas of controlled drug release, such as photopharmacolo-
gy,[9] nanomedicine,[10] and image-guided drug transport.[11] In
particular, the unique application of these molecules to the
fluorescence-based imaging of intracellular prodrug activa-
tion[11e, f, 12] is enabled by the multifunctional design capacity of
the photocleavable cages, which allows for both a reporter
fluorophore and a drug molecule to be attached to the same
cleavable molecule. The spatially and temporally controlled re-
lease of both drug and imaging molecules within target cells
allows for monitoring of the extent of drug release with a re-
porter readout in real-time.[11a–d] Of these cages, the ONB cage,
which is the best characterized for its cleavage by one-
photon[1] and two-photon[4b, 5a, 6a] absorption, has played a signif-
icant role in the advancement of controlled drug release.[2, 13]
Despite its limited penetration through the skin (depth,
0.2 mm),[14] long-wavelength UVA (315–400 nm) has the ability
to reach as far as the subcutaneous layer. UVA is less toxic to
most mammalian cells than shorter UVB and UVC, and thus
has served as a tool for active control in chemical biology,
such as in protein activation,[3a, 5a, 15] optogenetics,[4a, c, 16] and in
the photochemical internalization of bio-macromolecules.[17]
More recently, applications of light-controlled mechanisms for
drug release[13] have been developed by numerous laborato-
ries, including ours, for the design of prodrugs and drug deliv-
ery systems for various therapeutic agents, including olaparib
(AZD-2281),[11e] melphalan,[11f] methotrexate,[18] doxorubicin
(Dox),[10b, c, 19] paclitaxel (Taxol),[20] 5-fluorouracil,[21] tamoxi-
Despite the immense potential of existing photocaging tech-
nology, its application is limited by the paucity of advanced
caging tools. Here, we report on the design of a novel thioace-
tal ortho-nitrobenzaldehyde (TNB) dual arm photocage that
enabled control of the simultaneous release of two payloads
linked to a single TNB unit. By using this cage, which was pre-
pared in a single step from commercial 6-nitroverataldehyde,
three drug–fluorophore conjugates were synthesized: Taxol-
TNB-fluorescein, Taxol-TNB-coumarin, and doxorubicin-TNB-
coumarin, and long-wavelength UVA light-triggered release
experiments demonstrated that dual payload release occurred
with rapid decay kinetics for each conjugate. In cell-based
assays performed in vitro, dual release could also be controlled
by UV exposure, resulting in increased cellular fluorescence
and cytotoxicity with potency equal to that of unmodified
drug towards the KB carcinoma cell line. The extent of such
dual release was quantifiable by reporter fluorescence mea-
sured in situ and was found to correlate with the extent of cy-
totoxicity. Thus, this novel dual arm cage strategy provides
a valuable tool that enables both active control and real-time
monitoring of drug activation at the delivery site.
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fen,[4a, 8, 16] and ciprofloxacin.[22] However, efficient implementa-
tion of photocage molecules for such applications[13] is often
challenging, due in part to the synthetic complexity involved
in drug and/or reporter conjugation, which requires a multistep
process. Some of the applications involving nanoparticulate
carrier systems required modification for presenting two at-
tachable ends–one to the drug (or reporter probe), and the
other to a particulate carrier.[10c, 11a, 19, 21, 23] The design of photo-
cage molecules as linkers for non-particulate, small molecule
applications is particularly difficult as compared to the carrier-
based ones, as reflected by the scarcity of validated functional
linkers.[11f, 24] In addition, fewer photocage linkers have been
implemented for the control of drug release[22–23] as compared
to other types of linkers with release mechanisms triggered by
cellular factors or conditions such as low pH,[13] reactive thi-
ols,[11b, 25] and metabolic enzymes.[11f, 26]
In this study, we designed a dual-arm photocage molecule
that provides both convenience in synthesis and payload con-
jugation and incorporates an externally controlled active re-
lease mechanism (Scheme 1 B). This photocage is based on
a novel thioacetal ortho-nitrobenzaldehyde (TNB), which is
cleaved in response to light exposure. This photocage strat-
egy[24–25] allows for the active control of release, unlike other
cleavable linkers that primarily rely on chemical and metabolic
mechanisms that occur passively in response to cellular fac-
tors.[13] Here, we evaluated the practical application of this TNB
cage for fluorescence-based monitoring of drug release by
cross-tethering both an anticancer agent and a fluorescent
probe to the cage. This dual conjugation strategy allows for
light-controlled drug release and concomitant activation of the
fluorescent reporter, which can be quantified in situ. As cellular
cytotoxicity is directly correlated with the intracellular concen-
tration of drug released, information regarding the efficiency
of this release system can be obtained from the fluorescence
readout. Thus, the intracellular kinetics and extent of drug re-
lease can be followed and measured on a real-time basis. This
article reports on the design of three anticancer TNB reporter
conjugates with proof of concept application validated for
light-controlled drug release and real-time monitoring in cellu-
lar systems.
Results and Discussion
Rationale of TNB design
Despite extensive use, the ONB cage presents only a single
cleavage site and is not optimal for dual arm, design which re-
quires two attachment sites per cage. In order to address this
design barrier and expand the applications of the ONB cage,
we designed a TNB system in which the benzylic position is
flanked by two identical arms, each connected with a C@S
bond instead of a C@O bond (Scheme 2). Accordingly, each of
the two arms has the potential for conjugation to a targeting
ligand, drug, or reporter molecule, and has the ability to re-
lease the two payloads simultaneously by light-controlled
cleavage of each C@S bond. This light control adds the benefit
of selective payload release, as the thioacetal, which is often
used as the protecting group for carbonyl compounds, is
stable under a wide range of physiological conditions and is
only susceptible to degradation under harsh synthetic condi-
tions with oxidative or extremely acidic reagents.[27]
Synthesis of TNB cages
Two types of TNB photocages, 1 and 2 (Scheme 2), each termi-
nated with a carboxylic acid or alcohol, respectively, were syn-
thesized with 76–89 % yield from commercial 6-nitroveratalde-
hyde and a requisite thiol (2.4 mol equiv) in a condensation re-
action catalyzed by BF3·Et2O (1.2 mol equiv) and acetic acid
(2.4 mol equiv) at ~0 8C (Schemes S2 and S3 in the Supporting
Information): MS (ESI ; m/z): 1 = 428.0 [M+Na]+ ; 2 = 372.0
[M+Na]+ . This one-step synthetic methodology confers rapid
access to various TNB photocages on a multigram scale. It is
similarly applicable to other aromatic aldehyde precursors
used in photocaging, such as 7-(diethylamino)coumarin-4-car-
Scheme 1. A) The photocaging strategy, as illustrated with a conventional
single arm photocage, ortho-nitrobenzyl (ONB); B) A dual arm strategy
based on a thioacetal ortho-nitrobenzaldehyde (TNB) photocage that ena-
bles the synchronous release and activation of a fluorescent reporter probe
(star) and a therapeutic molecule (sphere) upon triggering by light exposure.
Illustration of its application for fluorescence (FL)-monitored cellular drug ac-
tivation in vitro (below).
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boxaldehyde, which was readily converted to its thioacetal
form with 3-mercaptopropionic acid (not shown): MS (ESI ; m/
z): 462.0 [M+Na]+ , 440.0 [M+H]+ . In addition, each TNB photo-
cage has a symmetric thioacetal, which provides equal reactivi-
ty in each of its two arms during dual payload conjugation.
Synthesis of TNB conjugates
We illustrate the synthetic convenience of this TNB cage strat-
egy for dual payload conjugation by synthesizing three TNB
conjugates, 3–5. First, 1 TNB in which each arm is terminated
with a carboxylic acid coupled with Taxol at its C2’-OH to pre-
pare ester-based Taxol-TNB conjugate 6 (Scheme S2). The
other carboxylic acid remaining in the intermediate was subse-
quently conjugated with a reporter probe, including fluores-
cein methyl ester (fluorescein) or 4-methyl-7-coumarinol (cou-
marin), through an ester linkage. This sequential reaction led
to 3 (Taxol-TNB-fluorescein) and 4 (Taxol-TNB-coumarin), re-
spectively, and each conjugate was fully characterized by mass
spectrometry, 1H NMR spectroscopy and fluorescence spectros-
copy (Supporting Information): purity by analytical ultra-
performance liquid chromatography (UPLC): +95 % (3, 4) ; ESI
HRMS calcd for 3 (C83H80N2O25S2): 1569.4564 [M+H]
+ , found
1569.4542; calcd for 4 (C72H74N2O23S2): 1399.4203 [M+H]
+ ,
found 1399.4145; fluorescence spectroscopy 3 : lex = 480 (:5)
nm, lem = 520 (:5) nm; 4 : lex = 365 nm, lem = 445 nm.
Second, 2 TNB, which is functionalized with an alcohol in its
arm, was derivatized by coupling with 4-methyl-7-coumarinol
through carbonate formation, then with Dox through a carba-
mate linkage, resulting in 5 (Dox-TNB-coumarin; Scheme S3).
This TNB conjugate was characterized as above: analytical
UPLC purity (+95 %); ESI HRMS calcd for 5 (C52H52N2O22S2)
1138.2791 [M+NH4]+ , found 1138.2777; fluorescence spectros-
copy 5 : lex = 365 nm, lem = 445 nm.
Photolysis of TNB cages
UV/visible absorption spectra of TNB cages 1 and 2 were mea-
sured in an aqueous medium (Figure 1). Each showed a lmax at
346 nm (e= 5,950 (1) ; e= 4,292 (2) M@1 cm@1), which is slightly
longer than the lmax value of 340 nm for a conventional ONB
cage terminated with benzylic alcohol.[18b] This bathochromic
shift might be attributable to the effect of the sulfur atom
placed on the TNB cage, which is less electron withdrawing
than the benzylic oxygen in the ONB system.[28] The photolysis
of TNB cages 1 and 2 was performed by UVA exposure
(365 nm), and its progress was monitored by 1H NMR spectros-
copy, UV/visible spectrometry, and UPLC, each providing evi-
dence supportive of the cleavage mechanism proposed in Fig-
ure 1 A.
First, 1H NMR analysis of photolysed 1 showed time-depen-
dent disappearance of its benzylic proton (d= 6.02 ppm) at the
thioacetal group and concomitant growth of new aromatic sig-
nals in the upper field (Figure 1 B). This is indicative of oxida-
tion of the thioacetal to 2-nitrosobenzoic thioester, which is
believed to undergo subsequent hydrolysis to the 2-nitroso-
benzoic acid and 3-mercaptopropionic acid (detected as an
oxidized disulfide form; Figure S1). In addition to such hydro-
lytic cleavage, we anticipate that other types of chemical cleav-
age or ligation[29] might occur when it is cleaved in a cellular
environment through reactions with amines and thiols.
Second, UV/visible spectral traces acquired for each cage
showed a rapid decrease in absorbance at the lmax of each
compound for light exposure times of up to 2 min (Figure 1 C),
thus suggesting rapid photolytic cleavage of the TNB cage.
The quantum yield (Funcaging) of uncaging was determined by
ferrioxalate actinometry[30] for 1 and 2, which showed 0.20 and
0.19, respectively, as summarized in Table S1. Such spectral and
photophysical features were similarly observed in the photoly-
sis of the comparable ONB cage (Funcaging = 0.01–0.7).
[6b] Third,
Scheme 2. Structures of TNB-based photocages 1 and 2 and three TNB-derived compounds (3–5) in which each TNB molecule serves as a branching spacer
flanked by paclitaxel (Taxol) or doxorubicin (Dox) as a therapeutic molecule and a fluorescent reporter.
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UPLC analysis for photolysed 1 showed the appearance of
three new peaks, each at a shorter retention time (Figure S1),
which is consistent with the formation of smaller molecular
species, including the nitrosobenzoic acid and its (thio)esters.
Collectively, these data point to the photocleavage of the TNB
cage, yielding a 2-nitrosobenzoic acid product with the con-
comitant release of two thiol-terminated spacer molecules.
Light-controlled release kinetics
First, as a representative example, 3 (Taxol-TNB-fluorescein) in
an aqueous solution (water/MeOH, 1:1) was exposed to UVA
light (365 nm), and fluorescence spectra were measured
(Figure 2). The emission intensities were compared at 520 nm
(lem for fluorescein), showing an increase in emission as a func-
tion of exposure time (fourfold increase over a 10 min period).
We attributed this fluorescence change to the release of fluo-
rescein in its free phenolic form, which is characterized by
stronger fluorescence emission than the unreleased conjugat-
ed form. The increase in fluorescence is consistent with the
growth of an absorption peak at 485 nm (Figure S2 B), which is
indicative of fluorescein release. UPLC analysis was also per-
formed with the photolysed solutions. Area under the curve
(AUC) analyses indicated that the photolysis of 3 occurred
rapidly in a time-dependent manner with a decay half-life (t1/2)
of <2 min and Funcaging of 0.05 (Figure 2 B). The UPLC analysis,
in combination with LC-MS analysis, enabled detection of the
release of two payloads, fluorescein and Taxol (Figure S2).
We believe that such dual release occurs through the pro-
posed mechanisms described in Figure 2, in which a thiol-ter-
minated precursor (C, D) is formed initially by light-triggered
C@S bond cleavage, followed by intramolecular self-immola-
tion,[11f, 31] which leads to the release of the free payload spe-
cies. This release mechanism can also produce two other inter-
mediates (A, B), and these thiol ester-containing intermediates
can then each be converted to the thiol-terminated precursor
(C, D) through hydrolysis, transthioesterification,[29, 32] or amida-
tion[29] by water, thiols, amines, or other nucleophilic biomole-
cules in the cell. This mechanism was supported by the results
of the LC-MS analysis performed for Taxol-TNB (a reference
Figure 1. A) Proposed mechanism for the photolysis of 1 TNB(CO2H) by long-wavelength UVA light (365 nm); B)
1H NMR spectral traces (500 MHz) and proton
assignment for the photolysis products of 1 (2.5 mm in 20 % CD3OD/D2O); C) UV/Vis spectral traces for the photolysis of 1 and 2 ([1] = 25 mm ; [2] = 29 mm,
10 % aq. MeOH). Inset: plot of relative absorbance (A) at lmax (346 nm) as a function of exposure time.
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compound without a linked reporter molecule) after 2 min of
irradiation, which showed the release of precursor A along
with Taxol (Figure S3). Our proposed mechanism for Taxol re-
lease from precursor D is also in agreement with the drug re-
lease from a thiol-terminated alkanoyl taxoid[33] (a homologue
to the precursor D) by self-immolative cyclization, which was
pioneered by Ojima, et al.[31a] and others[11c, 34] using thiol-termi-
nated prodrugs. However, despite the same mechanism, the
rate of payload release from precursors C and D might be not
identical, due to the difference in their leaving group capabili-
ty. Thus, the release of fluorescein that occurs through a phen-
oxide anion (pKa = 6.3–6.8)
[35] could be faster than that of pacli-
taxel that occurs through an alkoxide anion (pKa>10). In sum-
mary, we believe that the present data, in combination with
existing knowledge, are supportive of dual payload release by
the self-immolative mechanism proposed here.
Light-controlled release studies were also performed with 4
(Taxol-TNB-coumarin) and 5 (Dox-TNB-coumarin), and photo-
lysed solutions were characterized as summarized in Figure 2
and by UV/visible spectrometry and LC-MS analysis (Figures S4
and S5). Photolysis of these led to a 2.4- or 4.7-fold increase in
fluorescence intensity, respectively, relative to the level before
light exposure (Figure 2). This enhanced fluorescence occurred
with the rapid disappearance of each TNB construct with
decay half-lives (t1/2) of <2 min in UPLC analysis and Funcaging
of 0.07 (4) and 0.08 (5). The UV/visible spectra indicated expo-
sure time-dependent rapid changes in absorption features. LC-
MS analysis of selected photolysed solutions provided evi-
dence supportive of the release of the free drug molecule and
coumarin. We believe that this release also occurs through an
intramolecular cyclization reaction involving an ester (4)[31a, 33]
or carbonate (5)[11c, 34] bond by the nucleophilic terminal thiol
on the drug or reporter precursor. It is notable that the quan-
tum efficiency (Funcaging) of uncaging determined for each con-
jugate (3–5) showed a ~ three- to fourfold decrease relative to
its parent TNB cage, as presented above. This decrease could
be attributable to photon absorption (such as a protective an-
tenna effect[36]) by a conjugated payload molecule such as flu-
orescein, coumarin, or dox, given the significant molar absorp-
tivity (e) of these compounds at the irradiation (UVA) wave-
length (Figures S2–S5).
Intracellular uptake and light-triggered release
To determine whether the TNB conjugates could be taken up
intracellularly and subsequently cleaved through light activa-
tion after uptake, cellular fluorescence was analyzed by using
flow cytometry. KB cells, an epithelial carcinoma line over-
expressing folic acid receptor (FAR(+)), were used as a model
system. Cells were incubated with 1.5 mm of 3 (Taxol-TNB-fluo-
rescein) in folic acid-free cell culture medium for 0, 2, 6, and
24 h at 37 8C (Figure 3). At the end of the incubation period,
unincorporated conjugate was removed by washing, and the
cells were then exposed to long-wavelength UVA (365 nm)
light for 2 min. For the incubation time of 0 h, the conjugate
was added to the cells and immediately washed off prior to
light exposure. Cellular fluorescein fluorescence (mean fluores-
cence intensity (MFI)) was then measured by flow cytometry.
The percentage of cells with fluorescence greater than the
intrinsic fluorescence of untreated cells was also determined
(Figure 3 C).
Taxol-TNB-fluorescein (3) was taken up intracellularly within
2 h of incubation, and continued to be taken up over 24 h, as
evidenced by the slight increase in the cellular MFI and the
percentage of cells with high fluorescence in the absence of
Figure 2. Photolysis of 3 (Taxol-TNB-fluorescein), 4 (Taxol-TNB-coumarin), and
5 (Dox-TNB-coumarin) in solution. A) Proposed mechanism for the light-
mediated dual payload release for 3 and the structures of precursor com-
pounds (A–D). B)–D) Release kinetics for 3, 4, and 5, as monitored by fluores-
cence spectroscopy (left). Each plot (right) shows the remaining conjugate
(% AUC by UPLC; left axis) and the fold increase in fluorescence (lem = 520
or 450 nm) relative to the non-UV-treated control of each conjugate (right
axis) as a function of exposure time: [3] = 64 mm, [4] = 69 mm, and [5] =
62 mm.
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light exposure, attributed to the fluorescence of the uncleaved
conjugate (Figure 3 C). Upon light exposure, a large increase in
the cellular MFI and percentage of cells containing increased
fluorescence was observed for cells incubated with 3 (e.g. , 6.3-
fold increase in MFI and 6.0-fold increase in the percentage of
cells with increased fluorescence for cells treated with 1.5 mm
of 3 with 6 h of incubation prior to light exposure). The in-
crease in cellular fluorescence induced by light exposure in-
creased in magnitude with longer preincubation times be-
tween 0–6 h, reflecting the intracellular accumulation of the
conjugate (Figure 3 B, C). These results confirm that a significant
amount of the intact Taxol-TNB-fluorescein conjugate is taken
up intracellularly and is retained within the cell in a relatively
intact state that maintains the fluorescein reporter in a fluores-
cently quenched state. Furthermore, these results demonstrate
that UV-mediated photocleavage of the TNB construct can
occur intracellularly. The decrease in MFI and percentage of
fluorescent cells between 6 and 24 h, however, is attributed to
cell death due to the cytotoxic effects of the drug conjugate.
Correlation between fluorescence and cytotoxicity in vitro
To confirm the functional activity of the TNB conjugates and
the released drug, their cytotoxic properties were evaluated in
KB cells with or without exposure to UV. A microplate assay
that allowed measurement of fluorescence on a real-time basis
Figure 3. Determination of intracellular uptake by flow cytometry analysis. KB cells were incubated with 1.5 mm of 3 (Taxol-TNB-fluorescein) for the indicated
times (t = 0, 2, 6, and 24 h), washed to remove extracellular conjugate, and then exposed to UVA (365 nm) for 2 min or left in the dark. Cell-associated fluores-
cence (fluorescein channel) was measured by flow cytometry. A) Representative histograms showing the distribution of fluorescence intensities for intact cells
: light exposure. B) Changes in the average cellular mean fluorescence intensity (MFI) for treated cells, and C) the percentage of cells with fluorescence (FL)
higher than untreated cells.
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in live cells, and measurement of the viability of the same cells
by an XTT assay, was employed instead of the fluorimeter,
which was used for photolysis in solution (Figure 2). FAR(+) KB
cells were treated with 3, 4, and 5 at various concentrations
and exposed briefly to UVA light (365 nm) for 2 min (Figure 4).
The fluorescence of the reporter molecule was measured im-
mediately. A large increase in either fluorescein or coumarin re-
porter fluorescence (several orders of magnitude) was seen for
all three conjugates upon UV irradiation relative to treated
cells that were not exposed to UV. Fluorescein and coumarin
conjugates had similar low fluorescence emission intensities
prior to light activation at their respective excitation and emis-
sion wavelengths. Interestingly, for the Taxol-TNB conjugates,
the fluorescein-containing conjugate, 3, displayed an increase
in fluorescence of much greater magnitude compared to the
coumarin conjugate, 4 (Figure 4 A and B). This lower fluores-
cence exhibited by 4 might be explained, in part, by its lower
increase in fluorescence in solution after UV exposure (Fig-
ure 2 B and C).
The increase in reporter fluorescence upon light exposure
correlated with the concomitant increase in cytotoxicity of the
drug conjugates. Cytotoxicity displayed a dose dependency for
both non-UV- and UV-treated cells. Prior to UV exposure, 3, 4,
and 5 exhibited minimal cytotoxicity (IC50 values of 0.24, 0.23,
and 9.22 mm, respectively) compared to unconjugated doxoru-
bicin and Taxol (0.04, 0.02 mm, respectively ; Figure S6), thus
suggesting that conjugation might reduce systemic toxicity.
Upon UV exposure, the cytotoxicity of the conjugates in-
creased dramatically, decreasing the IC50 values by an order of
magnitude (IC50 values for 3, 4, and 5 : 0.04, 0.05, and 0.84 mm,
respectively). As controls, no effect of light exposure on cell vi-
ability or fluorescence intensity (inset) was observed for either
free Taxol or doxorubicin, both of which were highly cytotoxic,
even at low nanomolar concentrations (Figure S6). These re-
sults demonstrate the ability to actively control the cytotoxicity
of these constructs temporally and support the utility of fluo-
rescence readouts as a means for monitoring the amount of
drug transported to the target cell and accordingly, for predict-
ing tumor cell viability in situ.
Real-time release kinetics
The positive correlation observed between fluorescence and
cytotoxicity above is supportive of the ability to exert spatio-
temporal control on drug release and perform quantitative
monitoring of the extent of release indirectly by using fluores-
cence measurements in real-time. In order to characterize the
release kinetics in cellular systems, we determined the extent
of additional reporter release (reflective of drug release), over
time after the initial UV stimulus by following the increase in
the fluorescence of live cells over 24 h of incubation at 37 8C
(Figure 5). Incubation of cells treated with 3 or 4 and exposed
to UV (exposure time = 0.5 or 2 min) led to a rapid increase in
fluorescence within the first 3 h of incubation, followed by
a small gradual increase over the remaining 24 h. The endpoint
fluorescence after 24 h was more than twofold the fluores-
cence measured immediately after UV exposure. The continued
release of reporter and drug for an extended period after the
initial UV stimulus was not due to cleavage of the cage by cel-
lular factors, but this slow gradual increase was likely due to
Figure 4. Fluorescence intensity (A–C) measured by a microplate reader and cell viability (D–F) of FAR(+) KB cells treated with 3, 4, or 5, with or without expo-
sure to long-wavelength UV (365 nm) for 2 min (UV = 0, 2 min). Fluorescence was measured at lex = 485 nm, fluorescein release (3) at lem = 528 nm, and cou-
marin release (4, 5) at lex = 360 nm, lem = 460 nm immediately after the UV exposure period. Cell viability was measured by incubation of the cells treated
with each conjugate for 24 h post UV exposure, and then washed and grown for four additional days prior to measuring the viability with an XTT assay rela-
tive to untreated cells.
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the self-immolative conversion of transient dye intermediates
to a fully fluorescent dye molecule, as similar release kinetics
were observed in the cell-free control (Figure 5 D).
Interestingly, in contrast to conjugates 3 and 4, conjugate 5
showed only a minimal additional increase in fluorescence
over the course of 24 h following the initial jump in fluores-
cence immediately after 2 min of UV exposure. This suggests
that 2 min of UV exposure was sufficient to rapidly and fully re-
lease all of the coumarin in 5. Thus, dye release from light-ex-
posed 5 is likely to occur faster than from 3 or 4. We believe
that such differences among the three TNB conjugates might
be attributable to the mechanism and rate of the self-immola-
tion reaction[11c, 34] by which the fluorescent dye molecule is
converted from its respective thiol precursor. The thiol precur-
sor generated from 5 has a coumarin moiety attached to the
spacer through a more chemically reactive carbonate function-
ality which is thus more labile to nucleophilic displacement
reactions than the ester functionality present in the thiol pre-
cursors from 3 and 4.
Control cells that were treated with the conjugates but were
unexposed to UV showed only minimal changes in bulk report-
er fluorescence over 3 h of incubation, indicating stability of 3–
5 during the fluorescence measurement time period in the
fluorescence assay in Figure 4 and confirming the role of UV ir-
radiation in reporter activation. However, prolonged incubation
for 24 h led to some increase in reporter fluorescence for con-
jugates 3–5, even without light exposure, although the fluores-
cence at 24 h was still <30–50 % that of the light exposed
cells after 24 h. This “dark” release of reporter, and putatively
of drug, accounts for the degree of cytotoxicity observed for
the non-UV treated cells in Figure 4. This partial increase sug-
gests the possibility of dye release by other non-photochemi-
cal pathways, including ones not triggered by cleavage of the
C@S bond in the TNB cage, such as intermolecular nucleophilic
attack at the carbonate or ester bond by water, free amines,
and thiols. Involvement of these passive mechanisms might
similarly occur in the release of the drug payload. In particular,
TNB conjugates 3 and 4 each carry Taxol attached through an
ester bond, which is reportedly labile and cleaved by hydroly-
sis and lysosomal enzymes.[31a, 37] However, the stability of these
constructs over several hours makes them functional over the
time frame required for them to reach the target site for pho-
toactivation applications.
In order to enhance our understanding of this non-photo-
chemical background release, we investigated the effect of a
model thiol, 3-mercaptopropionic acid (1 mm :UV), on the re-
lease of coumarin by using TNB-coumarin as a model system
(Figure S7). When added at a ~5 molar equivalent, the thiol
lacked the ability to trigger the release of coumarin in the ab-
sence of UVA light exposure. In combination with light expo-
sure, the thiol played a clear role in altering the distribution of
thioester precursors and accordingly made an indirect contri-
bution to the dye release. This result, though observed in
a simple model system, was supportive of the earlier results
observed in the cellular system (Figure 5). Lastly, intracellular
esterase activity might contribute to the non-photochemical
background release, as these esterases are well known for their
role in the hydrolytic activation and intracellular trapping of
cell-permeable fluorogenic ester molecules.[38] A full under-
standing of all of the contributors to non-photochemical re-
lease requires the thorough design of various model studies
and constitutes the objective of future studies.
In summary, the extent of dye release was conveniently
measured in real-time by fluorescence in situ. The resulting
kinetics of dye release suggests that the release occurred
through a mechanism triggered by the photolytic C@S cleav-
age of the TNB cage and subsequently by other non-photo-
chemical mechanisms. Thus, measurements made shortly after
UV activation represent the extent of drug released as trig-
gered by the light stimulus, whereas measurements made over
an extended incubation time represent release of drug collec-
tively from a combination of photochemical and other mecha-
nisms.
Figure 5. Real-time monitoring of reporter fluorescence intensities under
three different exposure conditions. A)–C) The fluorescence of FAR(+) KB
cells treated with 3 (Taxol-TNB-fluorescein), 4 (Taxol-TNB-coumarin), or 5
(Dox-TNB-coumarin), each at 1.5 mm, was monitored by using a microplate
reader immediately after variable lengths of exposure to long-wavelength
UVA light (365 nm; UV = 0, 0.5, 2 min; marked with a blue double arrow).
Post exposure time = 0 h represents the fluorescence measured immediately
after UV exposure. The cellular fluorescence was subsequently followed over
the course of 24 h of additional incubation at 37 8C. D) The fluorescence in-
tensities of TNB conjugates 3, 4, and 5 in medium alone were monitored at
their respective excitation and emission wavelengths following 0.5 min of
UV exposure.
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Conclusion
Major challenges facing the development of controlled drug
release systems include the paucity of cage technologies that
allow for active control and for gauging in situ how much
drug is released from a cage system at a given dose.[11d, 39] We
have designed a novel TNB-based, dual arm cage with the
unique ability to trigger light-controlled synchronous release
of two payloads. Compared to existing bifunctional link-
ers,[11b, c, f, 25, 26, 40] it offers synthetic convenience, an active mech-
anism for the control of payload release by light exposure, and
rapid release kinetics comparable to an ONB cage system.[10b, 13]
Its practicality for fluorescence-based monitoring of drug re-
lease for in vitro cellular applications was investigated here by
its conjugation with Taxol or doxorubicin, along with a condi-
tionally fluorescent reporter. The conjugates exhibited a strong
correlation between drug release and fluorescence measured
in situ on a real-time basis. Furthermore, TNB conjugation was
also able to maintain the drug compounds in a reduced cyto-
toxic state in the conjugated form, and the conjugates were
taken up intracellularly at doses that were as cytotoxic as the
unmodified drug upon UV activation.
We believe that this new strategy will make a broad impact
on the advancement of fluorescence-based release control in
a wide range of applications ranging from those involving
small molecule drug–reporter conjugates to nanoparticulate
delivery systems. This strategy offers important tools to the ex-
panding field of photocaging,[2, 6b, 9] which has been applied
not only to organic molecules but also to metal ions by using
photolabile metal chelators,[41] such as acetal-based ONB,[42]
which employs a similar fragmentation reaction at its acetal
carbon. Finally, we believe that this TNB strategy has strong
potential for use as a new platform for photocaging thiols,
which can be used in the active control of cellular activities
that are mediated by bioactive thiols including cysteine,
among others. These applications range from the control of
redox biology,[43] enzymes,[15, 44] and ion channel permeability.[45]
As discussed above, the values of Funcaging that were deter-
mined for TNB-caged small thiols, including 1 and 2 (Table S1)
are comparable to ONB-caged molecules[6b] and are supportive
of the compatibility of such application. Future efforts will
focus on extending and validating the scope of this TNB strat-
egy in photocaged small molecules for chemical biology and
in nanoscale systems designed for receptor-targeted anticancer
therapeutic agents.
Acknowledgements
This work was supported by the Michigan Nanotechnology Insti-
tute for Medicine and Biological Sciences the National Cancer
Institute (NCI) of the National Institutes of Health (NIH)
(1R21A191428), and the British Council and Department for Busi-
ness Innovation & Skills through the Global Innovation Initiative.
Keywords: antitumor agents · caged compounds · controlled
release · dual arm cage · fluorescence reporter · photolysis
[1] J. W. Walker, J. A. McCray, G. P. Hess, Biochemistry 1986, 25, 1799 – 1805.
[2] G. Mayer, A. Heckel, Angew. Chem. Int. Ed. 2006, 45, 4900 – 4921; Angew.
Chem. 2006, 118, 5020 – 5042.
[3] a) E. A. Lemke, D. Summerer, B. H. Geierstanger, S. M. Brittain, P. G.
Schultz, Nat. Chem. Biol. 2007, 3, 769 – 772; b) B. N. Goguen, A. Aemis-
segger, B. Imperiali, J. Am. Chem. Soc. 2011, 133, 11038 – 11041.
[4] a) K. H. Link, Y. Shi, J. T. Koh, J. Am. Chem. Soc. 2005, 127, 13088 – 13089;
b) P. Neveu, I. Aujard, C. Benbrahim, T. Le Saux, J.-F. Allemand, S. Vriz, D.
Bensimon, L. Jullien, Angew. Chem. Int. Ed. 2008, 47, 3744 – 3746; Angew.
Chem. 2008, 120, 3804 – 3806; c) X. Lu, S. S. Agasti, C. Vinegoni, P. Water-
man, R. A. DePinho, R. Weissleder, Bioconjugate Chem. 2012, 23, 1945 –
1951.
[5] a) A. Momotake, N. Lindegger, E. Niggli, R. J. Barsotti, G. C. R. Ellis-
Davies, Nat. Methods 2006, 3, 35 – 40; b) M. M. Mahmoodi, D. Abate-
Pella, T. J. Pundsack, C. C. Palsuledesai, P. C. Goff, D. A. Blank, M. D. Di-
stefano, J. Am. Chem. Soc. 2016, 138, 5848 – 5859.
[6] a) T. Furuta, S. S. H. Wang, J. L. Dantzker, T. M. Dore, W. J. Bybee, E. M.
Callaway, W. Denk, R. Y. Tsien, Proc. Natl. Acad. Sci. USA 1999, 96, 1193 –
1200; b) P. Kl#n, T. Šolomek, C. G. Bochet, A. Blanc, R. Givens, M. Rubina,
V. Popik, A. Kostikov, J. Wirz, Chem. Rev. 2013, 113, 119 – 191.
[7] Y. M. Li, J. Shi, R. Cai, X. Chen, Z. F. Luo, Q. X. Guo, J. Photochem. Photo-
biol. A 2010, 211, 129 – 134.
[8] A. P. Gorka, R. R. Nani, J. Zhu, S. Mackem, M. J. Schnermann, J. Am.
Chem. Soc. 2014, 136, 14153 – 14159.
[9] M. M. Lerch, M. J. Hansen, G. M. van Dam, W. Szymanski, B. L. Feringa,
Angew. Chem. Int. Ed. 2016, 55, 10978 – 10999; Angew. Chem. 2016, 128,
11140 – 11163.
[10] a) Y.-H. Chien, Y.-L. Chou, S.-W. Wang, S.-T. Hung, M.-C. Liau, Y.-J. Chao,
C.-H. Su, C.-S. Yeh, ACS Nano 2013, 7, 8516 – 8528; b) S. K. Choi, T.
Thomas, M. Li, A. Kotlyar, A. Desai, J. R. Baker, Jr. , Chem. Commun. 2010,
46, 2632 – 2634; c) P. T. Wong, D. Chen, S. Tang, S. Yanik, M. Payne, J. Mu-
kherjee, A. Coulter, K. Tang, K. Tao, K. Sun, J. R. Baker, Jr. , S. K. Choi,
Small 2015, 11, 6078 – 6090.
[11] a) S. Impellizzeri, B. McCaughan, J. F. Callan, F. M. Raymo, J. Am. Chem.
Soc. 2012, 134, 2276 – 2283; b) S. Maiti, N. Park, J. H. Han, H. M. Jeon,
J. H. Lee, S. Bhuniya, C. Kang, J. S. Kim, J. Am. Chem. Soc. 2013, 135,
4567 – 4572; c) Z. Yang, J. H. Lee, H. M. Jeon, J. H. Han, N. Park, Y. He, H.
Lee, K. S. Hong, C. Kang, J. S. Kim, J. Am. Chem. Soc. 2013, 135, 11657 –
11662; d) G. M. Lanza, C. Moonen, J. R. Baker, E. Chang, Z. Cheng, P.
Grodzinski, K. Ferrara, K. Hynynen, G. Kelloff, Y.-E. K. Lee, A. K. Patri, D.
Sept, J. E. Schnitzer, B. J. Wood, M. Zhang, G. Zheng, K. Farahani, Wiley
Interdiscip. Rev. Nanomed. Nanobiotechnol. 2014, 6, 1 – 14; e) S. S. Agasti,
A. M. Laughney, R. H. Kohler, R. Weissleder, Chem. Commun. 2013, 49,
11050 – 11052; f) R. Weinstain, E. Segal, R. Satchi-Fainaro, D. Shabat,
Chem. Commun. 2010, 46, 553 – 555.
[12] O. Redy-Keisar, S. Ferber, R. Satchi-Fainaro, D. Shabat, ChemMedChem
2015, 10, 999 – 1007.
[13] P. T. Wong, S. K. Choi, Chem. Rev. 2015, 115, 3388 – 3432.
[14] R. R. Anderson, J. A. Parrish, J. Invest. Dermatol. 1981, 77, 13 – 19.
[15] a) D. Abate-Pella, N. A. Zeliadt, J. D. Ochocki, J. K. Warmka, T. M. Dore,
D. A. Blank, E. V. Wattenberg, M. D. Distefano, ChemBioChem 2012, 13,
1009 – 1016; b) D. P. Nguyen, M. Mahesh, S. J. Els-sser, S. M. Hancock, C.
Uttamapinant, J. W. Chin, J. Am. Chem. Soc. 2014, 136, 2240 – 2243.
[16] a) M. A. Inlay, V. Choe, S. Bharathi, N. B. Fernhoff, J. R. Baker, I. L. Weiss-
man, S. K. Choi, Chem. Commun. 2013, 49, 4971 – 4973; b) T. Faal, P.
Wong, S. Tang, A. Coulter, Y. Chen, C. H. Tu, J. R. Baker, S. K. Choi, M. A.
Inlay, Mol. BioSyst. 2015, 11, 783 – 790; c) D. K. Sinha, P. Neveu, N. Gagey,
I. Aujard, T. L. Saux, C. Rampon, C. Gauron, K. Kawakami, C. Leucht, L.
Bally-Cuif, M. Volovitch, D. Bensimon, L. Jullien, S. Vriz, Zebrafish 2010,
7, 199 – 204.
[17] P. K. Selbo, A. Weyergang, A. Høgset, O.-J. Norum, M. B. Berstad, M.
Vikdal, K. Berg, J. Controlled Release 2010, 148, 2 – 12.
[18] a) S. K. Choi, T. P. Thomas, M.-H. Li, A. Desai, A. Kotlyar, J. R. Baker, Photo-
chem. Photobiol. Sci. 2012, 11, 653 – 660; b) S. K. Choi, M. Verma, J. Silpe,
R. E. Moody, K. Tang, J. J. Hanson, J. R. Baker, Jr. , Bioorg. Med. Chem.
2012, 20, 1281 – 1290.
[19] M. M. Dcona, Q. Yu, J. A. Capobianco, M. C. T. Hartman, Chem. Commun.
2015, 51, 8477 – 8479.
[20] a) M. Noguchi, M. Skwarczynski, H. Prakash, S. Hirota, T. Kimura, Y. Haya-
shi, Y. Kiso, Bioorg. Med. Chem. 2008, 16, 5389 – 5397; b) M. Skwarczyn-
ChemBioChem 2017, 18, 126 – 135 www.chembiochem.org T 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim134
Full Papers
ski, M. Noguchi, S. Hirota, Y. Sohma, T. Kimura, Y. Hayashi, Y. Kiso, Bioorg.
Med. Chem. Lett. 2006, 16, 4492 – 4496.
[21] S. S. Agasti, A. Chompoosor, C.-C. You, P. Ghosh, C. K. Kim, V. M. Rotello,
J. Am. Chem. Soc. 2009, 131, 5728 – 5729.
[22] P. Wong, S. Tang, J. Mukherjee, K. Tang, K. Gam, D. Isham, C. Murat, R.
Sun, J. R. Baker, S. K. Choi, Chem. Commun. 2016, 52, 10357 – 10360.
[23] a) Q. Lin, C. Bao, Y. Yang, Q. Liang, D. Zhang, S. Cheng, L. Zhu, Adv.
Mater. 2013, 25, 1981 – 1986; b) Y. Yang, Q. Shao, R. Deng, C. Wang, X.
Teng, K. Cheng, Z. Cheng, L. Huang, Z. Liu, X. Liu, B. Xing, Angew. Chem.
Int. Ed. 2012, 51, 3125 – 3129; Angew. Chem. 2012, 124, 3179 – 3183.
[24] a) S. Karthik, B. N. Prashanth Kumar, M. Gangopadhyay, M. Mandal,
N. D. P. Singh, J. Mater. Chem. B 2015, 3, 728 – 732; b) S. Yamazoe, Q. Liu,
L. E. McQuade, A. Deiters, J. K. Chen, Angew. Chem. Int. Ed. 2014, 53,
10114 – 10118; Angew. Chem. 2014, 126, 10278 – 10282.
[25] S. Santra, C. Kaittanis, O. J. Santiesteban, J. M. Perez, J. Am. Chem. Soc.
2011, 133, 16680 – 16688.
[26] Y. Yuan, C.-J. Zhang, M. Gao, R. Zhang, B. Z. Tang, B. Liu, Angew. Chem.
Int. Ed. 2015, 54, 1780 – 1786; Angew. Chem. 2015, 127, 1800 – 1806.
[27] K. C. Nicolaou, C. J. N. Mathison, T. Montagnon, Angew. Chem. Int. Ed.
2003, 42, 4077 – 4082; Angew. Chem. 2003, 115, 4211 – 4216.
[28] A. R. Katritzky, Y.-J. Xu, A. V. Vakulenko, A. L. Wilcox, K. R. Bley, J. Org.
Chem. 2003, 68, 9100 – 9104.
[29] P. E. Dawson, M. J. Churchill, M. R. Ghadiri, S. B. H. Kent, J. Am. Chem.
Soc. 1997, 119, 4325 – 4329.
[30] C. G. Hatchard, C. A. Parker, Proc. R. Soc. London Ser. A 1956, 235, 518 –
536.
[31] a) I. Ojima, Acc. Chem. Res. 2008, 41, 108 – 119; b) R. LabruHre, A.
Alouane, T. Le Saux, I. Aujard, P. Pelupessy, A. Gautier, S. Dubruille, F.
Schmidt, L. Jullien, Angew. Chem. Int. Ed. 2012, 51, 9344 – 9347; Angew.
Chem. 2012, 124, 9478 – 9481.
[32] Y. Hori, T. Norinobu, M. Sato, K. Arita, M. Shirakawa, K. Kikuchi, J. Am.
Chem. Soc. 2013, 135, 12360 – 12365.
[33] I. Ojima, X. Geng, X. Wu, C. Qu, C. P. Borella, H. Xie, S. D. Wilhelm, B. A.
Leece, L. M. Bartle, V. S. Goldmacher, R. V. J. Chari, J. Med. Chem. 2002,
45, 5620 – 5623.
[34] a) I. R. Vlahov, G. D. Vite, P. J. Kleindl, Y. Wang, H. K. R. Santhapuram, F.
You, S. J. Howard, S.-H. Kim, F. F. Y. Lee, C. P. Leamon, Bioorg. Med. Chem.
Lett. 2010, 20, 4578 – 4581; b) A. Kock, K. Zuwala, A. A. A. Smith, P. Ruiz-
Sanchis, B. M. Wohl, M. Tolstrup, A. N. Zelikin, Chem. Commun. 2014, 50,
14498 – 14500.
[35] L. D. Lavis, T. J. Rutkoski, R. T. Raines, Anal. Chem. 2007, 79, 6775 – 6782.
[36] H. Staleva, J. Komenda, M. K. Shukla, V. Šlouf, R. Kaňa, T. Pol&vka, R. So-
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